Home / Letter From The Editor / Sept. 22, 2016

Sept. 22, 2016

Sep 22, 2016


For years many of us have lamented the butchering that Dr. Steven Nissen gave to the TZDs. Part of this came from the extra cardiovascular studies that every manufacturer had to do on new diabetes drugs that came to market. Many of you thought that those studies were useless and only added time and extra expenses to the approval process. But we might actually have to thank the good doctor for his direction, as these studies are now showing the positive cardiovascular effects of drugs like Cycloset, Januvia, Invokana and the like.

This month we are focusing on the cardiovascular benefits of the DPP-4i’s and why they are a great choice either alone or in combination with other medications, such as metformin.


Dave Joffe